Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 83-95

  Postow, Michael A ^a   Yuan, Jianda ^a   Kitano, Shigehisa ^a   Lesokhin, Alexander M ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Absolute lymphocyte count; CTLA 4; Immunologic response biomarkers; Inducible costimulator; Ipilimumab; Myeloid derived suppressor cells; NY ESO 1 antigen; Tremelimumab

Indexed keywords

CYTOKINE; IPILIMUMAB; NY ESO 1 ANTIGEN; TETRAMER; TICILIMUMAB;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CELL SEPARATION; CELL STIMULATION; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; LYMPHOCYTE COUNT; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; STAINING; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BLOOD SPECIMEN COLLECTION; CELL SEPARATION; CRYOPRESERVATION; CTLA-4 ANTIGEN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; MONITORING, IMMUNOLOGIC; PHENOTYPE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891766012     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_6     Document Type: Article

References (26)

1. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
2. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
3. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454
4. Berman D, Wolchok J, Weber J et al (2009) Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 27(suppl): 15s.3020 (abstr
5. Ku GY, Yuan J, Page DB et al (2010) Singleinstitution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 116: 1767-1775
6. Postow M, Yuan J, Panageas K et al (2012) Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). J Clin Oncol 30(suppl):8575, abstr
7. Yang A, Kendle RF, Ginsberg BA et al (2010) CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes. J Clin Oncol 28(suppl):15s.2555, abstr
8. Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005-3010
9. Hamid O, Schmidt H, Nissan A et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204
10. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372-8377
11. Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053
12. Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 12:1005-1016
13. Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455-463
14. Comin-Anduix B, Lee Y, Jalil J et al (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22
15. Burmeister Y, Lischke T, Dahler AC et al (2008) ICOS controls the pool size of effectormemory and regulatory T cells. J Immunol 180:774-782
16. Liakou CI, Kamat A, Tang DN et al (2008) CTLA-4 blockade increases IFNgammaproducing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105: 14987-14992
17. Carthon BC, Wolchok JD, Yuan J et al (2010) Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-2871
18. Wang W, Yu D, Sarnaik AA et al (2012) Biomarkers on melanoma patient T Cells associated with ipilimumab treatment. J Transl Med 10:146
19. Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856-860
20. Yuan J, Adamow M, Ginsberg BA et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefi t in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108:16723-16728
21. Klein O, Ebert LM, Nicholaou T et al (2009) Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 15:2507-2513
22. Weide B, Zelba H, Derhovanessian E et al (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30:1835-1841
23. Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocytemacrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546-2553
24. Poschke I, Mougiakakos D, Hansson J et al (2010) Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70: 4335-4345
25. Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925-931
26. Kitano S, Postow M, Cortez C et al (2012) Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma. J Clin Oncol 30(suppl):2518, abstr